Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure

September 21,2024

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

Revolutionary Advancements in Hypertension Treatment: Zilebesiran Redefines the Landscape

Zilebesiran's Long-Lasting Antihypertensive Potential - Cardiac Wire

Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease

Exploratory Analyses in the Monotherapy Study

Future treatments in hypertension: Can we meet the unmet needs of patients? - ScienceDirect

Entering a New Era of Antihypertensive Therapy - American Journal of Kidney Diseases

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Topline phase 2 data show potent, dose-dependent BP reduction with zilebesiran

Professor Bryan Williams MD FMedSci on LinkedIn: Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in…

Innovative Treatment for Hypertension: One Shot Every Quarter or Even Six Months • BioPharma Media

Treatment for Mild Chronic Hypertension during Pregnancy

Vol 80, No 11